SKG0106

GENETIC3 trials

Sponsors

Skyline Therapeutics (US) Inc., Youxin Chen, Skyline Therapeutics

Conditions

Neovascular (Wet) Age-related Macular DegenerationNeovascular Age-related Macular Degeneration

Phase 1

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

RecruitingNCT05986864

Skyline Therapeutics (US) Inc.Neovascular Age-related Macular Degeneration

Start: 2024-02-23End: 2027-01-30Target: 68Updated: 2026-08-28

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

CompletedNCT06213038

Youxin ChenNeovascular Age-related Macular Degeneration

Start: 2023-05-05End: 2025-11-21Updated: 2026-09-11

Unknown Phase

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

RecruitingNCT06346600

Skyline TherapeuticsNeovascular (Wet) Age-related Macular Degeneration

Start: 2025-04-02End: 2031-03-01Target: 83Updated: 2026-09-01